Elutia, Inc.
ELUT
Positions held
Your positionsELUT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $36.64M | Enterprise value | $21.12M | Trailing P/E | — | Forward P/E | -0.75 |
| PEG | — | Price / book | 2.32 | Beta | 0.84 | Dividend yield | 0.00% |
| Revenue growth | -11.6% | Earnings growth | — | Gross margin | 57.8% | Operating margin | -2.4% |
| Profit margin | 4.3% | ROE | — | ROA | -34.7% | Debt / equity | 0.28 |
| Current ratio | 1.77 | Free cash flow | -$27.47M | Analyst recommendation | strong_buy | Mean target | $5.00 |
| 52w high | $1.39 | 52w low | $0.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $2.4M | $3.1M | $3.3M | $3.3M | $2.7M | — |
| Op margin | -243.1% | -184.4% | -167.9% | -131.1% | -158.8% | — |
| Net income | -$7.6M | -$7.5M | $70.8M | -$3.9M | -$9.6M | — |
| Gross margin | 59.6% | 57.9% | 58.5% | 55.8% | 52.9% | — |
| Gross profit | $1.4M | $1.8M | $1.9M | $1.9M | $1.5M | — |
| Operating income | -$5.9M | -$5.7M | -$5.5M | -$4.4M | -$4.4M | — |
- Revenue -22% vs prior quarter ($2.4M vs $3.1M).
- Gross margin 59.6% (was 57.9% prior quarter).
- Operating margin compressed to -243.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $12.3M | $14.5M | $24.7M | $23.8M | — |
| Op margin | -149.8% | -133.7% | -83.0% | -125.7% | — |
| Net income | $53.4M | -$53.9M | -$37.7M | -$32.9M | — |
| Gross margin | 53.7% | 46.4% | 44.7% | 48.8% | — |
| Gross profit | $6.6M | $6.7M | $11.1M | $11.6M | — |
| Operating income | -$18.4M | -$19.3M | -$20.5M | -$30.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Elutia Reports $8 Million Payment from Boston Scientific
2026-10-01 · Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
2026-09-10 · Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
2026-08-20 · Elutia (ELUT) Q2 2026 Earnings Call Transcript
2026-08-18 · Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
2026-08-18 · Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
2026-08-14 · Elutia Inc. Q2 2026 Earnings Call Summary
2026-08-14 · Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ...
2026-08-13 · Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
2026-08-12 · Earnings To Watch: Elutia Inc (ELUT) Q2 2026 -- GF Value Sees 6% Downside
Price (daily)
Full chart · RSI · MACD · patterns